The exploratory head-to-head study evaluated the safety and efficacy of Akston’s Ambifect platform, which triggers the animal's immune system to produce endogenous antibodies against Nerve Growth Factor. By neutralizing the NGF-TrkA binding pathway, the treatment addresses chronic pain at its biological source. Data indicated that both candidates provided meaningful reductions in pain scores and orthopedic assessment improvements, with effects lasting through the 56-day evaluation period. In a supplemental durability cohort, AKS-548d maintained detectable antibody responses up to 120 days, raising the prospect of extending intervals between treatments.

Unlike traditional monoclonal antibodies that require weight-based dosing and frequent veterinary visits, Akston’s approach leverages the immune system’s natural scaling, which may allow for fixed-dose administration. The study reported a positive safety profile for both candidates, with no serious treatment-related adverse events and stable clinical pathology markers across the subjects. While the initial study was not designed as a large-scale efficacy trial, the results provide a foundation for upcoming blinded, placebo-controlled evaluations in client-owned dogs. If these outcomes are replicated in broader clinical settings, the platform could significantly reduce the logistical and financial burden currently associated with long-term osteoarthritis management in pets.